Noveris Health Sciences Inc. MYCOF

Company Overview

Noveris Health Sciences Inc. is a publicly traded health sciences company associated with the development of biotechnology and wellness-related products, with historical activity tied to psychedelic medicine research, drug development, and health-focused consumer products. The company’s shares have traded on the OTC market under the ticker MYCOF, and public disclosures indicate that the business has undergone strategic and corporate transitions over time, including changes in branding and operational focus. Publicly available information suggests the company has explored opportunities in mental health therapeutics, pharmaceutical research, and related intellectual property development.

Available public filings and market disclosures indicate that the company has historically pursued commercialization opportunities connected to emerging health science sectors, particularly those involving novel therapeutic compounds and mental health treatment models. However, several operational and financial details are difficult to independently confirm through current public filings alone, and some historical disclosures appear tied to predecessor entities or prior corporate structures. Data inconclusive based on available public sources.

Business Operations

Historically, the company’s operations have been associated with biotechnology research and product development initiatives targeting mental health and wellness applications. Public disclosures linked to predecessor operations referenced activities involving psychedelic-assisted therapy research, pharmaceutical formulation development, and health technology initiatives. Revenue generation historically appears to have been limited and primarily connected to early-stage commercial activities, licensing efforts, or capital market financing rather than mature recurring operating income.

The company’s operational footprint appears to have included both North American research activities and relationships with external scientific, clinical, or manufacturing partners. Public records also reference intellectual property development and research collaborations associated with therapeutic compounds and drug delivery technologies. Information regarding current operating subsidiaries, active joint ventures, or material revenue-producing business units could not be consistently verified across multiple recent public sources. Data inconclusive based on available public sources.

Strategic Position & Investments

Noveris Health Sciences Inc.’s historical strategic direction appears to have focused on participation in emerging health science and biotechnology markets, particularly those related to mental health therapeutics and alternative treatment modalities. Prior investor materials and public statements associated with the company referenced efforts to develop differentiated intellectual property portfolios, pursue clinical research pathways, and establish positions within rapidly evolving regulatory environments tied to psychedelic medicine and wellness innovation.

The company has also been associated with acquisition activity and strategic investments intended to expand research capabilities and product development pipelines. Publicly available information references prior interests in technology platforms, research partnerships, and therapeutic development programs, although the current status of many of these initiatives is not fully verifiable through recent independently confirmed filings. Data inconclusive based on available public sources.

Geographic Footprint

Public disclosures indicate that the company has maintained operational and corporate connections primarily within North America, including activities associated with Canada and the United States. Historical filings and investor materials suggest the company pursued research, commercialization, and capital market activities targeting both domestic and international health sciences markets.

The company’s securities have traded in public markets accessible to U.S. investors through the OTC market, while prior corporate activity appears to have involved Canadian regulatory filings and business operations. There is limited independently verified evidence of significant large-scale international operating infrastructure outside North America. Data inconclusive based on available public sources.

Leadership & Governance

Publicly available information regarding current executive leadership and governance structure is limited and, in some cases, inconsistent across market data providers and historical filings. Earlier corporate disclosures associated with predecessor operations identified leadership teams with backgrounds in biotechnology, pharmaceuticals, and capital markets. However, current executive and board composition could not be fully verified through consistently updated public filings.

Known or historically associated executives referenced in public disclosures include:

• Joshua Bartch – Former Chief Executive Officer
• Damon Michaels – Former Chief Operating Officer
• Rob Roscow – Former Chief Financial Officer

Historical leadership communications emphasized growth through innovation in health sciences, intellectual property development, and participation in emerging therapeutic sectors. Current governance structure and strategic leadership priorities could not be conclusively verified based on available public sources.